Immunwork Inc. has spent 10 years perfecting its breakthrough therapies, with two ultra-long-acting peptide drugs now in clinical trials! The company is on track for a potential public listing by late 2025 or 2026!
 
Pipeline Highlights:

• TE-8105: An ultralong-acting GLP-1 drug for weight loss, aiming to challenge Novo Nordisk & Eli Lilly! 
• TE-8214: An ultralong-acting octreotide analogue, requiring just one injection per month for better treatment adherence! 

 
Immunwork is paving the way for world-class, long-acting therapies!
 
Read more: https://news.gbimonthly.com/tw/magazine/article_show.php?num=64567
 
Follow #Globalbio for more insights into biomedical sciences!
#TaiwanBiotech #AntibodyPioneer #ChangTseWen #Immunwork #NewDrugDevelopment #GLP1 #BiotechInnovation